D. Menchaca

The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.

R. Beveridge, C. Abboud, E. Waller, 2002, Experimental hematology.

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.

J. Rasko, C. Begley, J. Zalcberg, 1997, Blood.

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer

C. Begley, J. Rasko, C. Begley, 1996, The Lancet.

Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.

C. Begley, C. Begley, M. Edmonds, 2002, Blood.

Overview of the safety and biologic effects of peg‐rhumgdf in clinical trials

W. Sheridan, D. Menchaca, 1998, Stem cells.

Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.

C. Begley, J. Collins, J. Szer, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo

G. Demetri, S. Galli, A. Dvorak, 1996, The Journal of experimental medicine.

Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients.

E. Shpall, L. Chap, J. Glaspy, 1997, Blood.

Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin‐releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer

M. Garnick, S. Baughman, D. Menchaca, 2003, Clinical pharmacology and therapeutics.

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.

R. Figlin, J. Crawford, L. Harker, 1997, The New England journal of medicine.